The Phase 2b study demonstrated a statistically significant dose-response relationship at the primary endpoint following a single administration of MM120 across four dose levels, with improvements ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly ...

Efbemalenograstim Alfa, a Long-Acting Granulocyte Colony-Stimulating Factor Fusion Protein Without PEGylation, Versus Pegfilgrastim for Management of Chemotherapy-Induced Neutropenia in Patients With ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

Controversy persists regarding the appropriate duration of therapy with benzathine penicillin G in persons with early (i.e., primary, secondary, or early latent) syphilis (Treponema pallidum infection ...

Low-dose megestrol enhances hormone therapy for ER-positive breast cancer, reducing tumor proliferation and improving ...

The trial, led by a team of scientists and physicians at Mass General Brigham hospital in Boston, was investigating the ...